Vir Biotechnology Inc

Vir Biotechnology, Inc. is a privately held company based in San Francisco, California. With 143 employees, the company has generated $500 million in revenue. Vir Biotechnology focuses on developing innovative immunology treatments for infectious diseases and beyond. Vir Biotechnology specializes in engineering monoclonal antibodies (mAbs) using a proprietary platform enhanced by machine learning and artificial intelligence. This technology allows them to develop transformative medicines for diseases with a significant global impact. Their current pipeline includes clinical candidates targeting hepatitis B and delta viruses, human immunodeficiency virus (HIV), influenza A and B viruses, COVID-19, respiratory syncytial virus/human metapneumovirus, and human papillomavirus. Additionally, they are developing an investigational T cell vaccine to prevent HIV. Vir Biotechnology distinguishes itself through its robust research and development capabilities, combining proprietary antibody platforms with cutting-edge technologies. The company actively collaborates with industry leaders, government agencies, and non-profit organizations to accelerate scientific advancements and translate discoveries into tangible benefits for patients worldwide. For more information, visit Vir Biotechnology's website at vir.bio.